Company Profiles

driven by the PitchBook Platform

Alethia Biotherapeutics

Description

Developer of monoclonal antibody based therapeutics. The company is engaged in the discovery and development of therapeutic against disease tissue specific novel clinically relevant targets.

2002

Founded

PRIVATE

Status

11-50

Employees

Corporate

Latest Deal Type

$16.4M

Total Amount Raised

5

Investors

Description

Developer of monoclonal antibody based therapeutics. The company is engaged in the discovery and development of therapeutic against disease tissue specific novel clinically relevant targets.

Website:

www.alethiabio.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Primary Office

141, President-Kennedy Avenue Suite SB-5100 Montreal, Quebec H2X 1Y4Canada +1 (514) 858-7666
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Alethia Biotherapeutics's full profile, request a free trial.

Alethia Biotherapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Alethia Biotherapeutics Investors (5)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
BDC Healthcare Venture FundVenture CapitalMinority000 0000000 0000
CellscriptCorporationMinority000 0000000 0000
Epicentre TechnologiesCorporationMinority000 0000000 0000
GeneChem ManagementVenture CapitalMinority000 0000000 0000
IBC GeneriumOtherMinority000 0000000 0000
BDC Healthcare Venture Fund Venture Capital
Cellscript Corporation
Epicentre Technologies Corporation
GeneChem Management Venture Capital
IBC Generium Other

Alethia Biotherapeutics Executive Team (8)

NameTitleBoard
Seat
Contact
Info
Yves CornellierPresident, Chief Executive Officer and Board of Director
Mario Filion Ph.DExecutive Vice President & Chief Scientific Officer
Janique Forget Ph.DDirector, Intellectual property
Julie Laurin Ph.DDirector, Preclinical Drug Development
Gilles Tremblay Ph.DVice President, Research
Yves Cornellier President, Chief Executive Officer and Board of Director
Mario Filion Ph.D Executive Vice President & Chief Scientific Officer
Janique Forget Ph.D Director, Intellectual property
Julie Laurin Ph.D Director, Preclinical Drug Development
Gilles Tremblay Ph.D Vice President, Research

Alethia Biotherapeutics Board Members (4)

NameRepresentingRoleSinceContact
Info
Ela BorensteinBDC Healthcare Venture FundBoard Member000 0000
Elizabeth Douville Ph.DGeneChem ManagementBoard Member000 0000
Michael Berendt Ph.DSelfInterim Chairman000 0000
William Boyle Ph.DAlethia BiotherapeuticsBoard Member000 0000
Ela Borenstein Board Member BDC Healthcare Venture Fund
Elizabeth Douville Ph.D Board Member GeneChem Management
Michael Berendt Ph.D Interim Chairman Self
William Boyle Ph.D Board Member Alethia Biotherapeutics
Request full access to PitchBook